P.013 Patient preferences for selection of preventive migraine therapies in Canada: results from a discrete choice experiment von Bougie, JK, Ladouceur, M, Martin, A, Beusterien, K

Volltext

P.004 Real-world effectiveness of intravenous eptinezumab in patients with chronic migraine and previous subcutaneous preventive migraine treatment von Argoff, C, Herzog, SP, Smith, RM, Soni-Brahmbhatt, S, Awad, SF, Asher, D, Khan, F, Bougie, JK, Miron, J

Volltext

P.005 Eptinezumab demonstrated efficacy regardless of prior preventive migraine treatment failure: post hoc DELIVER analyses von Pozo-Rosich, P, Ashina, M, Tepper, SJ, Jensen, S, Pickering Boserup, L, Krog Josiassen, M, Sperling, B, Bougie, JK, Miron, J

Volltext

ASSESSMENT IN WORK PRODUCTIVITY AND THE RELATIONSHIP WITH COGNITIVE SYMPTOMS (ATWORC): PRIMARY ANALYSIS FROM A CANADIAN OPENLABEL STUDY OF VORTIOXETINE IN PATIENTS WITH MAJOR DEPRE... von Bougie, JK, Chokka, P, Rampakakis, E, Proulx, J

Volltext

REAL LIFE ASSESSMENT OF ABILIFY MAINTENA (RELIAM): INTERIM ANALYSIS FROM A CANADIAN NATURALISTIC STUDY OF ARIPIPRAZOLE LONG-ACTING INJECTABLE IN PATIENTS WITH SCHIZOPHRENIA von Bougie, JK, Malla, A, Miguelez, M, Proulx, J

Volltext

P.027 Efficacy and Safety of Eptinezumab Initiated During a Migraine Attack: Results from the RELIEF Study von Winner, PK, McAllister, P, Chakhava, G, Ailani, J, Mehta, L, Ettrup, A, Krog Josiassen, M, Lindsten, A, Bougie, JK, Cady, R

Volltext